The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discussses the results of a retrospective study evaluating the use of bone marrow assessment of minimal residual disease (MRD) as a surrogate endpoint in patients with multiple myeloma receiving CAR T-cell therapy. Bone marrow MRD negativity was associated with prolonged survival and those who were MRD positive at 1 month were highly unlikely to convert to MRD negative. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
